Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $245,386.83 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 9,391 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were purchased at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the acquisition, the chief financial officer directly owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Sensei Biotherapeutics Price Performance

Shares of FTH opened at $22.87 on Monday. The company has a market cap of $30.65 million, a P/E ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a 12 month low of $6.32 and a 12 month high of $36.76.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. HC Wainwright began coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target for the company. Weiss Ratings began coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday. They set an “outperform” rating and a $57.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.